Stephen Harrow

Stephen Harrow

Auto-generated profile, based on publicly available information

Stephen Harrow

Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DPDavid Palma
David Palma
Robert Anton OlsonRobert Anton Olson
Robert Anton Olson
SHStephen Harrow
Stephen Harrow
RCRohann J. M. Correa
Rohann J. M. Correa
FSFamke Schneiders
Famke Schneiders
SSSuresh Senan
Suresh Senan
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions. One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology (Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-specified systemic therapy (Group 1: immunotherapy/targeted; Group 2: cytotoxic; Group 3: observation). SABR is to be completed within 2 weeks, allowing for rapid initiation of systemic therapy. Recommended SABR doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, chosen to minimize risks of toxicity. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, time to development of new metastatic lesions, quality of life, and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA, and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of response and long-term survival. This study will provide an assessment of the impact of SABR on clinical outcomes and quality of life, to determine if long-term survival can be achieved for selected patients with 4–10 oligometastatic lesions. Clinicaltrials.gov identifier: NCT03721341 . Date of registration: October 26, 2018.

1 November 2020 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
GWGerard M. Malachy Walls
Gerard M. Malachy Walls
JOJamie B. Oughton
Jamie B. Oughton
ACAnthony Chalmers
Anthony Chalmers
SBSarah Brown
Sarah Brown
FCFiona Collinson
Fiona Collinson
AGAlastair Greystoke
Alastair Greystoke
• Lung cancer is the leading cause of cancer mortality worldwide. • Gold standard chemoradiotherapy is not deliverable for the majority of patients. • Radiation-induced DNA damage repair is an actionable mechanism of radioresistance. • Careful trial design is essential to elicit maximum impact on therapeutic index. • CONCORDE is a platform study of novel drug/radiotherapy combinations in lung cancer.

14 May 2024 in Lung Cancer
Verified
Journal Article
Closed access
IMIndu S. Voruganti Maddali
Indu S. Voruganti Maddali
CCCicely Cunningham
Cicely Cunningham
LMLorraine McLeod
Lorraine McLeod
HBHouda Bahig
Houda Bahig
NCNazia Chaudhuri
Nazia Chaudhuri
ALAlexander Louie
Alexander Louie

30 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
DPDavid Palma
David Palma
Robert Anton OlsonRobert Anton Olson
Robert Anton Olson
SHStephen Harrow
Stephen Harrow
SGStewart Gaede
Stewart Gaede
ALAlexander Louie
Alexander Louie
SSSuresh Senan
Suresh Senan
Purpose: The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. Methods: We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial. Results: Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms. Conclusions: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. ( NCT01446744 ) Funding: Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant

11 April 2018 in Clinical Oncology
Verified
Journal Article
Closed access
PDF file
GHGerard G Hanna
Gerard G Hanna
FMF. McDonald
F. McDonald
LMLouise Murray
Louise Murray
SHS. Harrow
S. Harrow
DLD. Landau
D. Landau
KFK.N. Franks
K.N. Franks

11 December 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DPDavid Palma
David Palma
HCHanbo Chen
Hanbo Chen
HBHouda Bahig
Houda Bahig
SGStewart Gaede
Stewart Gaede
SHStephen Harrow
Stephen Harrow
CRChristopher J. Ryerson
Christopher J. Ryerson
Background: Stereotactic ablative radiotherapy (SABR) has become an established treatment option for medically-inoperable early-stage (Stage I-IIA) non-small cell lung cancer (ES-NSCLC). SABR is able to obtain high rates of local control with low rates of symptomatic toxicity in this patient population. However, in a subset of patients with fibrotic interstitial lung disease (ILD), elevated rates of SABR-related toxicity and mortality have been described. The Assessment of Precision Irradiation in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease (ASPIRE-ILD) study will conduct a thorough prospective evaluation of the clinical outcomes, toxicity, changes in diagnostic test parameters and patient-related outcomes following SABR for ES-NSCLC for patients with fibrotic ILD. Methods: ASPIRE-ILD is a single-arm Phase II prospective study. The accrual target is 39 adult patients with T1–2N0M0 non-small cell lung cancer with co-existing ILD who are not candidates for surgical excision. Pathological confirmation of diagnosis is strongly recommended but not strictly required. Enrolled patients will be stratified by ILD-related mortality risk. The starting SABR dose will be 50 Gy in 5 fractions every other day (biologically effective dose: 100 Gy10 or 217 Gy3), but the radiation dose can be de-escalated up to two times to 50 Gy in 10 fractions daily (75 Gy10 or 133 Gy3) and 45 Gy in 15 fractions daily (58 Gy10 or 90 Gy3). Dose de-escalation will occur if 2 or more of the first 7 patients in a cohort experiences grade 5 toxicity within 6 months of treatment. Similarly, dose de-escalation can also occur if 2 or more of the first 7 patients with a specific subtype of ILD experiences grade 5 toxicity within 6 months of treatment. The primary endpoint is overall survival. Secondary endpoints include toxicity (CTC-AE 4.0), progression-free survival, local control, patient-reported outcomes (cough severity and quality of life), rates of ILD exacerbation and changes in pulmonary function tests/high-resolution computed tomography findings post-SABR. Discussion: ASPIRE-ILD will be the first prospective study specifically designed to comprehensively evaluate the effectiveness and safety of SABR for ES-NSCLC in patients with co-existing ILD. Trial registration: Clinicaltrials.gov identifier: NCT03485378. Date of registration: April 2, 2018.